As depression apps proliferate, physicians face important questions. What should they know, and do these tools have a role in ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta ...
The funding includes €2 million ($2.35 million) in seed investment from Critical Path Ventures and €1 million ($1.18 million) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback